Evodiamine: A Comprehensive Reference
1. Identity and Chemical Characterization
1.1 Chemical Names and Classification
Evodiamine (EVO) is a tryptamine indole alkaloid and the main active ingredient in Evodia rutaecarpa. It is more precisely categorized as an indoloquinazoline (or quinazolinocarboline) alkaloid. Evodiamine, a racemic quinazolinocarboline alkaloid isolated from the traditional Chinese medicine Evodiae fructus, has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo. Its molecular formula is C₁₉H₁₇N₃O.
1.2 Botanical Source
Evodiamine was first isolated in 1915 by Japanese chemists Yuji Asahina and Kazuko Kashiwaki from the unripe fruits of Evodia rutaecarpa (now classified as Tetradium ruticarpum), a member of the Rutaceae family native to East Asia. The name "evodiamine" directly derives from the genus Evodia under which the source plant was then categorized, reflecting its botanical origin. Subsequent taxonomic revisions in the late 20th century reclassified the genus, but the compound's nomenclature remained unchanged.
Evodiae fructus (Wu-Zhu-Yu in Chinese) is the dried, unripe fruit of Tetradium ruticarpum, also known as Euodia rutaecarpa. Evodia (Evodia rutaecarpa) is a seasonal tree native to northern China and Korea that bears small, reddish-brown fruit. Harvesting typically occurs in autumn when the fruits are unripe and green, as this stage maximizes the concentration of bioactive alkaloids. In dried fruits of E. rutaecarpa, evodiamine constitutes approximately 0.5–1% by dry weight, occurring alongside structurally related alkaloids such as rutaecarpine and evodine.
1.3 Major Co-occurring Constituents
The major constituents of Evodia rutaecarpa are evodiamine and rutaecarpine. Key constituents of the plant include indoloquinazoline alkaloids (including evodiamine, rutaecarpine, and dehydroevodiamine), limonene, daucosterol, triacontanoic acid, nonacosane, and beta-sitosterol. Evodiae fructus is widely used as a dietary supplement to provide carboxylic acids, essential oils, flavonoids, and other phytochemicals.
1.4 Common Preparations and Supplement Forms
The fruit is harvested and dried, then extracted, concentrated, and re-dried for use in modern preparations. In the case of oral administration, a pure preparation, a purified product, or a partially-purified product of an evodiamine compound can be administered as it is, or in the form of compositions such as tablets, powders, fine granules, granules, capsules, and syrups containing pharmaceutically acceptable excipients. In the contemporary dietary supplement market, evodiamine is most commonly sold as standardized extracts of the whole fruit or as isolated alkaloid preparations. EVO has poor solubility and low bioavailability; several derivatives with high antitumor activity have been discovered through the structural optimization of EVO, and new drug delivery systems have been developed to improve its solubility and bioavailability.
2. Traditional and Historical Use
2.1 Use in Traditional Chinese Medicine (TCM)
Evodiamine is one of the main bioactive components of Evodia rutaecarpa. It has been used for several hundred years as traditional Chinese medicine and was first recorded in the Shennong Herbal Classic. Evodiae fructus is traditionally used as a medicinal herb in China, Japan, and Korea.
Evodia rutaecarpa is a very popular multi-purpose herb traditionally used in China for the treatment of headaches, abdominal pain, postpartum hemorrhage, dysentery, and amenorrhea. Evodia rutaecarpa fruit has been used since at least the first century A.D. in traditional Chinese medicine (TCM). It is characterized as having a warm nature and an acrid, bitter, slightly toxic taste, although the fruit is quite fragrant. It is used to treat symptoms of abdominal distress, including nausea, vomiting, and diarrhea. It is also used to stimulate the appetite and to treat abdominal symptoms associated with lack of interest in food.
It is used in TCM to warm the body and is one of the few herbs classified as "hot" in nature. This classification reflects its perceived ability to dispel cold and alleviate cold-type conditions in the TCM framework. Evodiamine has long been used in traditional Chinese herbal medicine to treat pain, vomiting, and pyresis.
2.2 Classical Formulas and Use in Japan and Korea
Evodiae fructus combined with Coptidis rhizome at a ratio of 6:1 (w/w) forms the well-known Chinese medicinal formula, Zuo-Jin-Wan, which is commonly used to treat different types of cancer including gastric and multidrug-resistant colorectal cancer cells. Evodiae fructus is known as "Goshuyu" in the Japanese Kampo tradition, where it appears in several classical prescriptions targeting gastrointestinal complaints, cold-type pain, and headache.
3. Key Constituents and Mechanisms of Action
3.1 Primary Molecular Targets
Up to the current date, three proteins are believed to be direct targets of evodiamine, including TRPV1, the aryl hydrocarbon receptor (AhR), and topoisomerases I and II. These proteins seem to be important in inflammation, cancer, and other diseases.
3.2 TRPV1 Agonism and Thermogenesis
Evodiamine has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo. Evodiamine is structurally different from all known TRPV1 activators, and has significant clinical potential as a thermogenic agent. The TRP(V1) is a calcium ion channel, activated by pH, heat, and inflammatory activators. It is implicated in pain sensing.
Evodiamine appeared to prevent obesity and reduce body fat. The major mechanism eliciting the effect was postulated to be enhancement of uncoupling protein-1 (UCP1) thermogenesis through β3-adrenergic stimulation in brown adipose tissue (BAT). However, this mechanism has been called into question by later research. When UCP1-knockout mice were fed a high-fat diet with 0.03% evodiamine (wt/wt) for 2 months, the increases in body weight, adiposity, and the serum levels of leptin and insulin were reduced in a manner indistinguishable from control mice fed a high-fat diet with evodiamine, suggesting that evodiamine triggered a UCP1-independent mechanism to prevent diet-induced obesity.
3.3 Anti-Tumor Mechanisms
EVO can exert a range of different physiological mechanisms, including inhibition of proliferation, induction of apoptosis, reduction of migration/invasion, and inhibition of metastasis. More specifically:
- EVO suppresses cell proliferation by blocking cell cycle progression at G2/M phase by concurrently inhibiting Myt-1 and activating Cdc25C phosphatase, which significantly increases the activation of the Cdc2/cyclin B complex. In addition, EVO downregulates cyclin A expression, which induces S-phase arrest in cancer cells.
- Evodiamine was shown to exert antiproliferative activity against human leukemia cells (THP-1, K562, CCRF-CEM, and camptothecin-resistant CCRF-CEM/C1) by inactivating topoisomerase I (topo I) and II (topo II). In addition, the formation of cleavage complexes of topoisomerases with DNA was not affected by evodiamine.
- The possible mechanisms related to its anti-cancer activity as illustrated by different experimental studies include its potential action as modulator of specific receptors such as topoisomerase I, NF-κB, and B-cell lymphoma 2 (Bcl2).
- Blockade of angiogenesis also contributes to the anticancer activity of EVO.
3.4 Anti-Obesity and Metabolic Mechanisms
Evodiamine increased phosphorylation of ERK/MAPK in preadipocyte cultures, reduced the expression of transcription factors such as peroxisome proliferator-activated receptor-γ, and strongly inhibited adipocyte differentiation. There is a significant decrease in the mammalian target of rapamycin (mTOR) and ribosomal S6 protein kinase (S6K) signaling in white adipose tissue (WAT) in KK-Ay mice treated with evodiamine, in which glucose tolerance is improved. In addition, reduction of insulin receptor substrate 1 (IRS1) serine phosphorylation, an indicator of insulin resistance, was detected in their WAT, suggesting suppression of the negative feedback loop from S6K to IRS1.
Evodiamine was found to stimulate phosphorylation of AMP-activated protein kinase (AMPK), a cellular energy sensor, in adipocyte cultures and in evodiamine-treated WAT. Intragastric administration of evodiamine suppressed the neuropeptide Y (NPY) mRNA and peptide levels in the arcuate nucleus (ARC) of the hypothalamus, which might be one of the mechanisms by which evodiamine exerted its fat loss effects.
3.5 Neuroprotective Mechanisms
Evodiamine can ameliorate the blood–brain barrier (BBB) permeability and improve cognitive impairment by attenuating cellular apoptosis, decreasing oxidative stress, and reducing inflammation in ischemia and AD mouse models. Evodiamine can increase p-GSK3β Ser9 expression, an inhibited form of GSK3β, which is the major kinase causing tau phosphorylation.
3.6 Anti-Inflammatory and Analgesic Mechanisms
Evodiamine selectively inhibited upregulation of TRPV1 without affecting TRPV4 and reduced pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6, MCP-1) in the dorsal root ganglia. Evodiamine significantly reduced F4/80+ macrophage infiltration and shifted macrophage polarization from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype.
3.7 Pharmacokinetics
EVO has poor solubility and low bioavailability. Studies were conducted to investigate the metabolic characteristics of evodiamine in human liver microsomes and hepatocytes. A total of 12 phase I metabolites were detected in human liver microsomes; whereas in human hepatocytes 19 metabolites, including seven phase II metabolites, were detected. CYP1A2 and CYP3A4 were the main CYP450 enzymes affecting the elimination of EVO. Evodiamine undergoes metabolic bioactivation to form reactive metabolites, and evodiamine is a time-dependent inhibitor of CYP3A4. These results provided some clues in interpreting the mechanism of hepatotoxicity of evodiamine.
4. Scientific Evidence by Area of Use
4.1 Anti-Obesity and Weight Management
Animal and cellular evidence:
Several studies have demonstrated reduced fat accumulation and body weight after evodiamine supplementation in mice and rats. In preadipocytes, evodiamine increased phosphorylation of ERK/MAPK, which suggests that evodiamine potentially prevents the development of obesity partly via the inhibition of adipocyte differentiation through ERK activation. A recent study showed that supplementation with low-dose evodiamine prevented body weight gain in mice via increased AMPK phosphorylation and down-regulated mTOR signaling responsible for energy metabolism regulation in WAT.
Human (clinical) evidence:
In a randomized double-blind clinical trial, the body mass index (kg/m²) in premenopausal women was significantly reduced after administration of an Evodia extract in capsules (evodiamine 6.75 mg, rutaecarpine 0.66 mg). However, this finding is tempered by a contradictory result: another randomized controlled trial found that acute ingestion of 500 mg evodiamine at rest followed by 30 min of moderate exercise was ineffective in terms of thermogenesis induction and enhanced fat oxidation in men.
Evidence strength: Weak for human use. The thermogenic potential of evodiamine has made it popular in the health food market as a non-pungent slimming agent, even though this activity has never been conclusively demonstrated in the clinic, and only relies on animal and cellular experiments. Controlled human trials are rare. The available randomized crossover trial assessing acute thermogenesis found no effect from a 500 mg evodiamine dose on resting energy expenditure or substrate use in men. Robust trials examining multi-week dosing for weight, glycemia, pain, or performance outcomes are lacking.
4.2 Anti-Cancer Activity
Preclinical (in vitro and animal) evidence:
Growing evidence demonstrates that evodiamine possesses anti-cancer activities both in vitro and in vivo by inhibiting proliferation, invasion and metastasis, and inducing apoptosis of a variety of tumor cell lines. The antitumor effects of EVO have been reported mainly in colon cancer, lung cancer, hepatocellular carcinoma, and melanoma, suggesting that EVO may exert more favorable effects in the treatment of these tumors.
In lung cancer cell lines, the anti-proliferative effects of evodiamine in A549 cells were associated with cell cycle arrest at the G2/M phase and induction of apoptosis, suggesting that evodiamine is an effective natural compound for the treatment of lung cancer. (Note: this result is from a cell-line study only and does not constitute clinical evidence.)
Evodiae fructus combined with Coptidis rhizome at a ratio of 6:1 (w/w) forms the well-known Chinese medicinal formula Zuo-Jin-Wan, which is commonly used to treat different types of cancer including gastric and multidrug-resistant colorectal cancer cells.
Human (clinical) evidence:
Evidence strength: Preliminary. Despite extensive preclinical investigation, there are no completed randomized controlled trials evaluating evodiamine as a standalone anti-cancer treatment in humans. The evidence base consists entirely of cell-line and animal studies. Evodiamine is an alkaloid with attractive multitargeting antiproliferative activity. Its high content in the natural source ensures its adequate supply on the market and guarantees further medicinal study.
4.3 Neuroprotection and Alzheimer's Disease
Animal and cellular evidence:
Evodiamine, a major component of Evodia rutaecarpa, has been reported to possess various pharmacological activities, including anti-inflammatory, antioxidative stress, and neuroprotective effects. Earlier studies showed potential effects of evodiamine on the learning and memory impairments in the transgenic mouse model of Alzheimer's disease (AD).
Daily oral administration with evodiamine (50 or 100 mg/kg per day) starting from the first dose of streptozotocin (STZ) for 21 days showed an improvement in STZ-induced cognitive deficits as assessed by novel object recognition and Morris water maze test (in mice). Evodiamine significantly reduced the expression of phospho-tau, and further decreased tau aggregation and neuronal cell death in response to okadaic acid treatment. This inhibition was found to be via the inhibition of glycogen synthase kinase 3β (GSK3β), cyclin-dependent kinase 5, and mitogen-activated protein kinase pathways.
Evodiamine reduces the expression of inflammatory cytokines in senescence-accelerated mouse/prone 8 (SAMP8) and amyloid precursor protein and presenilin 1 (APPswe/PS1ΔE9) transgenic mouse models of AD, and increases the uptake of glucose in brain tissues.
Human (clinical) evidence:
Evidence strength: Preclinical only. All neuroprotection data for evodiamine in the context of AD and cognitive impairment are from in vitro cell studies or animal models. No clinical trials in human populations have been reported.
4.4 Anti-Inflammatory and Analgesic Effects
Preclinical evidence:
Evodiamine shows considerable pharmacological activities, including analgesic, anti-inflammatory, anti-tumor, anti-microbial, heart protection, and metabolic disease regulation. In a rat model of chemotherapy-induced peripheral neuropathy (CIPN): Evodiamine dose-dependently alleviated paclitaxel-induced mechanical and thermal allodynia both acutely and preventively. Evodiamine attenuated paclitaxel-induced p38 MAPK phosphorylation in dorsal root ganglia neurons, with selective p38 MAPK inhibition confirming this pathway's critical involvement in TRPV1 regulation and pain modulation. These are preclinical (animal) findings.
Evidence strength: Preclinical only. The analgesic and anti-inflammatory findings are animal- or cell-based and have not been confirmed in human clinical trials.
4.5 Gastrointestinal Effects
Preclinical evidence:
Evodiamine may regulate gastrointestinal motility, but the evidence is insufficient, and the mechanisms remain unknown. In in vitro rat colon studies: CCK1R was observed in smooth muscle cells, intermuscular neurons, and mucosa of rat colon. Evodiamine could inhibit spontaneous muscle contractions; nitric oxide synthase inhibitor L-NAME and CCK1R antagonist could partly block this effect.
Evidence strength: Preliminary/Preclinical. Gastrointestinal effects are supported by traditional use and supported by in vitro mechanistic work, but controlled human studies are lacking.
4.6 Cardiovascular Effects
Preclinical evidence:
Administered chronically, evodiamine also produces TRPV1-dependent protection against atherosclerosis in mice. In recent years, the antitumor, cardioprotective, anti-inflammatory, and anti-Alzheimer's disease effects of EVO have been reported. Several studies have indicated that evodiamine and rutaecarpine in Evodia may potentially have anti-atherosclerotic and cardioprotective effects.
Evidence strength: Preclinical only. No clinical trials have assessed evodiamine as a cardiovascular protective agent in humans.
4.7 Antimicrobial Effects
Topoisomerase I inhibitor evodiamine acts as an antibacterial agent against drug-resistant Klebsiella pneumoniae, according to a study published in Planta Med. (2013). This finding is from microbiological (in vitro) research and has not been evaluated in clinical settings.
5. Body Systems and Health Areas of Association
Based on the accumulated body of preclinical literature, evodiamine has been associated with effects on the following body systems:
- Metabolic/Adipose: Anti-obesity, anti-adipogenic, insulin-sensitizing, and glucose-regulatory effects demonstrated in rodent models.
- Oncology: Antiproliferative and pro-apoptotic effects observed across numerous human cancer cell lines (colon, lung, liver, melanoma, leukemia, breast, prostate, bladder) and some xenograft models.
- Central Nervous System: Neuroprotective and anti-Alzheimer's potential, with tau phosphorylation reduction and cognitive improvement in mouse models.
- Inflammatory/Immune: Modulation of NF-κB, TNF-α, IL-1β, IL-6, and macrophage polarization.
- Gastrointestinal: Inhibition of smooth muscle contraction; traditional use for nausea, vomiting, diarrhea, and abdominal pain.
- Cardiovascular: Preliminary evidence of anti-atherosclerotic and cardioprotective signaling via TRPV1; however, noted cardiac toxicity at higher exposures.
- Nociception/Pain: TRPV1-mediated analgesic activity consistent with the capsaicin-receptor pathway.
6. Dosage Forms and Reported Dosages
In the clinical trial examining BMI in premenopausal women, an Evodia extract in capsule form was administered, delivering evodiamine 6.75 mg and rutaecarpine 0.66 mg per serving. The contradictory randomized controlled trial used acute ingestion of 500 mg evodiamine.
In animal studies: UCP1-knockout mice were fed a high-fat diet with 0.03% evodiamine (wt/wt) for 2 months. Daily oral administration with evodiamine at 50 or 100 mg/kg per day for 21 days was used in the mouse Alzheimer's model. Mice were fed standard chow with 1 or 10 mg evodiamine per kg food, estimated as 0.1 or 1 mg evodiamine per kg body weight per day, respectively.
There is no universally established or regulatory-approved dosage for human supplementation. Controlled human trials are rare. In terms of pharmaceutical research context, one patent-based reference suggests when the agent is orally administered to an adult, it is suitable to administer an evodiamine compound as an active ingredient in an amount of 0.1–2000 mg/day in 1 to 4 parts, but this represents a research formulation range, not a clinical recommendation.
7. Safety Considerations and Drug Interactions
7.1 Hepatotoxicity
Hepatotoxicity and cardiotoxicity have sparked intense debate and research into the safety of evodiamine. In terms of hepatotoxicity, according to the literature, evodiamine could decrease the viability of L-02 cells and enhance the activity of aspartate transaminase (AST), expression of alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP).
Exposure to 45 ng/mL or higher concentrations of EVO led to significant hepatotoxicity in zebrafish models. Hepatotoxicity induced by EVO primarily involved the crosstalk of PPAR/PI3K/AKT/NF-κB/Tight Junction/Apoptosis signaling pathway.
7.2 Cardiotoxicity
In vivo, evodiamine induced cardiac malfunction as evidenced by changes in heart rate and circulation, and pericardial malformations. This study indicated that evodiamine could cause cardiovascular side effects involving oxidative stress. These findings suggest that cardiac function should be monitored in patients receiving preparations containing evodiamine.
Low doses of EVO (< 35 ng/mL) exhibited distinct analgesic activity without any adverse effects in zebrafish. However, EVO dose-dependently led to gross morphological abnormalities in the liver, followed by pericardial edema, and increased myocardial concentrations at higher doses.
7.3 Nephrotoxicity
Current research has found that EVO could have toxic effects, such as hepatotoxicity, nephrotoxicity, and cardiac toxicity. Nephrotoxicity has been associated with disruption of calcium homeostasis; one published study specifically investigated maintaining calcium homeostasis as a strategy to alleviate nephrotoxicity caused by evodiamine.
7.4 CYP450 Enzyme Inhibition and Drug Interactions
Evodiamine undergoes metabolic bioactivation to form its reactive metabolites, and evodiamine is a time-dependent inhibitor of CYP3A4. These results provided some clues in interpreting the mechanism of hepatotoxicity of evodiamine. EVO is susceptible to metabolism and may inhibit the activities of metabolizing enzymes, such as cytochrome P450.
CYP3A4 is a major drug-metabolizing enzyme responsible for the clearance of a large number of pharmaceutical agents, including statins, certain immunosuppressants, antiretrovirals, and many others. Time-dependent inhibition of CYP3A4 implies the potential for clinically relevant drug-drug interactions. Research in a rat model specifically found that evodiamine co-administered with pravastatin (a statin drug) altered systemic exposure in a non-alcoholic steatohepatitis model, with evodiamine and pravastatin administered by oral gavage once daily for 14 days.
7.5 Overall Safety Assessment
Evodiamine shows considerable pharmacological activities, such as analgesic, anti-inflammatory, anti-tumor, anti-microbial, heart protection, and metabolic disease regulation. However, it is also found that it has significant hepatotoxicity and cardiotoxicity, thereby it should be monitored in clinical use. Available data demonstrate that evodiamine has needy solubility in aqueous medium. Scientific and reasonable pharmaceutical strategies should be introduced to improve the above defects. Meanwhile, more efforts should be made to develop novel efficient and low-toxic derivatives.
8. Summary of Evidence Status
Evodiamine represents an area of substantial preclinical interest but limited clinical validation. Its pharmacological plausibility is well-established across multiple mechanisms — TRPV1 agonism, topoisomerase inhibition, NF-κB suppression, and AMPK/mTOR pathway modulation — and these mechanisms have been extensively characterized in cell cultures and animal models. However, the transition from these preclinical findings to proven human benefit has not occurred for any of its major proposed applications. Human trial data are scarce, contradictory in key areas (particularly thermogenesis and weight loss), and largely absent for anti-cancer, neuroprotective, and anti-inflammatory claims. The compound's poor oral bioavailability, documented hepatotoxicity at higher doses, cardiotoxicity signals, and CYP3A4 inhibition represent meaningful barriers to routine use and underscore the need for further rigorous clinical evaluation before definitive therapeutic conclusions can be drawn.
References
Go back